Trevi Therapeutics: Pay

Trevi Therapeutics paid its 3 named executives $6.9M in total in FY2025 (Dec). CEO Jennifer Good was paid $3.9M of that.

Pay$100 in the stock at the end of FY21 → $1.6K
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Jennifer GoodPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
James Cassella, Ph.D.Chief Development Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Farrell Simon, Pharm. D.Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.8M. The CEO of Trevi Therapeutics was paid $3.9M, 31% below the median.

  1. 1Disc Medicine
  2. 2Spyre Therapeutics
  3. 3Anaptysbio
  4. 4Celldex Therapeutics
  5. 5Savara
  6. 6Trevi Therapeutics
  7. 7Arbutus Biopharma
  8. 8Anavex Life SciencesNot disclosed
  9. 9Astria TherapeuticsNot disclosed
  10. 10Belite BioNot disclosed
  11. 11Centessa PharmaceuticalsNot disclosed
  12. 12Dianthus TherapeuticsNot disclosed
  13. 13Edgewise TherapeuticsNot disclosed
  14. 14Janux TherapeuticsNot disclosed
  15. 15Kodiak SciencesNot disclosed
  16. 16Mineralys TherapeuticsNot disclosed
  17. 17Rapport TherapeuticsNot disclosed
  18. 18RezoluteNot disclosed
  19. 19Upstream BioNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.